https://pioneerinstitute.org/wp-content/uploads/MBTA-Subway-Returns-Feature.jpg 450 600 Eamon McCarthy Earls https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Eamon McCarthy Earls2019-04-01 16:48:532021-10-29 15:18:12MBTAAnalysis: A look inside the MBTA
The MBTA shuttles over a million passengers a day around Greater…
https://pioneerinstitute.org/wp-content/uploads/CloseupClock-1.jpg 739 1244 Mary Connaughton https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Mary Connaughton2017-02-20 12:34:192017-02-21 09:47:58The Clock is Ticking…….
The clock is ticking towards December 30, 2017. As part of…
https://pioneerinstitute.org/wp-content/uploads/Hubwonk-Template-36.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2021-08-24 07:52:382021-08-24 07:52:38Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag
Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.
https://pioneerinstitute.org/wp-content/uploads/Untitled-design-2-4.png 512 1024 William Smith https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png William Smith2021-05-17 10:18:482021-05-26 10:53:35A Rush to Judgment on Alzheimer’s Drug
The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.
https://pioneerinstitute.org/wp-content/uploads/Five-Reasons-Why-Drug-Rebates-Are-Harmful-to-Patients-and-to-the-Healthcare-System.png 512 1024 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2020-09-01 06:40:182020-12-11 12:09:06Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System
Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.
https://pioneerinstitute.org/wp-content/uploads/US-Dollar-bill-and-pills-1.jpg 1246 2409 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2016-10-13 06:32:152018-10-12 15:05:06Survey Finds Prescription Drug Prices Easy To Access, But Not Always Accurate
Wide variation found in price of generics, less for brand-name…
https://pioneerinstitute.org/wp-content/uploads/pharmacist-with-pills-1.jpg 1413 2126 Editorial Staff https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png Editorial Staff2016-04-07 08:19:412020-06-17 20:31:13Study: Are Drug Prices Driving Healthcare Cost Growth?
Study: Requiring Drug Companies to Disclose Price Methodologies,…